Navigation Links
Jennerex Appoints Lara Longpre to Chief Operating Officer
Date:8/25/2010

SAN FRANCISCO, Aug. 25 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced the appointment of Lara Longpre to the position of chief operating officer. Ms. Longpre will be responsible for the development of the company's lead product, JX-594, as well as Jennerex's other product candidates in development and will lead the clinical operations and research, manufacturing, regulatory and quality functions. Ms. Longpre has served as a consultant to Jennerex since 2009.

"Lara's extensive experience in developing therapeutics will make her a key member of our executive management team," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "Her systematic and meticulous approach to operations, combined with her demonstrated leadership ability, make Lara the ideal person to direct the development of JX-594 as we move toward late stage clinical trials in advanced liver cancer."

Ms. Longpre brings to Jennerex over 17 years of broad clinical research, operations, and leadership expertise in all stages of clinical development.  Prior to Jennerex, Ms. Longpre held the position of  senior vice president, clinical and corporate affairs at MedGenesis Therapeutix and held senior positions at PRA International, a global CRO, including vice president of proposals and contracts, vice president of quality and process management, director of global regulatory affairs, and director of operations. She has directly managed several pivotal Phase 3 trials, and has specific expertise in project management, clinical operations, and quality management systems, including achieving ISO 9001:2000 registration and ensuring Sarbanes-Oxley compliance while at an international CRO. Ms. Longpre holds an M.Sc. in Medical Science from Harvard Medical School, an MBA from Queens University, and B.A. from Cornell University.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics comp
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. West Pharmaceutical Services, Inc. Appoints New Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BOTHELL, Wash. , Sept. 23, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced two new additions to its Scientific Advisory Board.  ... and Anthony Davies , PhD. Dr. ...
(Date:9/22/2014)... BARCELONA, Spain , September 23, 2014 ... sponsors to meet health authorities, increasing rigor for trial ... The life sciences industry,s largest TMF survey to date ... sponsors that plan to provide auditors with remote access ... 32% of TMF owners surveyed in the ...
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 /PRNewswire/ ... is in mature stage. It is largely a ... endoscopy suite expansion. The mergers, acquisitions and partnerships ... Europe . This research service provides details ... competitive environment and pricing trends across the country. ...
Breaking Medicine Technology:BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3
... RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity ... today that it has entered into a definitive ... Clinical Innovations, LLC ("Clinical"), to The Pritzker Group, ...  Terms of the transaction were not disclosed. ...
... Amira Pharmaceuticals, Inc. announced today that it has ... lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme ... a number of diseases including rheumatoid arthritis, glioblastoma, lung, ... pleased to announce that we have identified an orally ...
Cached Medicine Technology:RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor 2
(Date:9/23/2014)... adolescents who suffer from sleep disturbance or habitual short ... to those who enjoy a good night,s sleep. The ... Sleep Medicine . , In a new study involving ... from Uppsala County, researchers from Uppsala University demonstrate that ... (less than 7 hours per day) increased the risk ...
(Date:9/23/2014)... Airbus Helicopters Inc. (AHI) is proud to announce that ... Vision Zero Aviation Safety Award recipient for development ... safety service the company provides the air medical industry. ... for Airbus Helicopters Inc., presented Protean CEO John Cornett ... Medical Transport Conference Annual Community Awards banquet Monday, Sept. ...
(Date:9/23/2014)... September 23, 2014 Visiting Nurse Association ... home health care, hospice and palliative care, and community-based ... the Opening Bell last week at the New York ... Jersey philanthropist and social entrepreneur to care for immigrant ... Group has always worked to meet the urgent healthcare ...
(Date:9/23/2014)... 23, 2014 Given the nondiscretionary ... Fruit and Vegetable Markets industry is ... prices benefited operators over the five years to ... preference and demographic trends, including a focus on ... per capita fruit and vegetable consumption declined at ...
(Date:9/23/2014)... health care in the early 20th century, helping ... But bacteria are also constantly outsmarting science, and ... more frequently. This week,s Speaking of Chemistry focuses ... discusses the prospects for new drugs. The episode ... your pills if you feel better? Check it ...
Breaking Medicine News(10 mins):Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 3Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 4Health News:NJ's Largest Nonprofit Home Health Care Agency Joins Deutsche Bank to Ring New York Stock Exchange Opening Bell 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... A new report released,today by the national consumer rights ... this country,s dangerous government-approved drugs and,devices have been marketed ... made safer only after women filed lawsuits., The ... Drug Companies,Fail To Protect Women and How Lawsuits Save ...
... consumer survey finds that 94 percent of Americans would ... CINCINNATI, Oct. 29 P&G (NYSE: PG ) ... remove more than 99,percent of pharmaceutical compounds from America,s ... 96 percent with PUR pitchers.* According to a,2008 investigation ...
... Access to their Health,Information and the Ability to ... 29 CVS Caremark today announced,an extension to ... who utilize the company,s pharmacy benefit management services ... information,online. Consumers are now able to link their ...
... Site Drives Fight Against Childhood,Obesity by Providing Daily Content ... 29 Troy (Mich.) Chamber of Commerce,s,Helen eWards Committee ... Excellence, sponsored by Miller Canfield. The Danialle Karmanos,Work It ... best site in the,Social Impact category and was also ...
... tissues was detected by immunohistochemistry (IHC), Western blotting ... Its correlation Western blotting and RT-PCR. Livin positivity ... with tumor progression. Expression of Livin and VEGF ... the fourth clinical stage, expression of Livin and ...
... to eradicate fatal parasite; first vaccines delivered following major ... Melbourne researchers that could eradicate a fatal form of ... and could soon be commercially available thanks to multi-million ... causes 50 million tapeworm infections and 50,000 deaths from ...
Cached Medicine News:Health News:New Report Shows How Drug Industry Immunity Would Endanger Women 2Health News:PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers* 2Health News:PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers* 3Health News:PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers* 4Health News:CVS Caremark Partners with Google Health to Provide Consumers with Online Access to their Prescription History through Caremark.com 2Health News:CVS Caremark Partners with Google Health to Provide Consumers with Online Access to their Prescription History through Caremark.com 3Health News:Danialle Karmanos' Work It Out (DKWIO) Site Earns Recognition for Web Excellence 2Health News:A potential targets for the prevention or treatment of esophageal carcinoma 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 3
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
Medicine Products: